The Use of Non-Specific Tracers in the Follow Up of Differentiated Thyroid Cancer: Results with Tc-99m Tetrofosmin Whole Body Scintigraphy

Acta Medica Austriaca

Volumn 23, Issue 1-2, 1996, Pages 69-75

  Lind, P ^a   Gallowitsch, H J ^a  

^a GENERAL HOSPITAL KLAGENFURT   (Austria)

Author keywords

Differentiated thyroid carcinoma; Follow up; Tc 99m sestamibi; Tc 99m tetrofosmin; TI 201; Whole body scintigraphy

Indexed keywords

DIAGNOSTIC AGENT; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; ORGANOPHOSPHORUS COMPOUND; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 1,2 BIS(BIS(2 ETHOXYETHYL)PHOSPHINO)ETHANE; TECHNETIUM TC 99M 1,2-BIS(BIS(2-ETHOXYETHYL)PHOSPHINO)ETHANE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; METASTASIS; MIDDLE AGED; PAPILLARY CARCINOMA; SCINTISCANNING; THYROID TUMOR; TUMOR RECURRENCE; WHOLE BODY COUNTING;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; TECHNETIUM TC 99M SESTAMIBI; THYROID NEOPLASMS; WHOLE-BODY COUNTING;

EID: 0029696060     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Hoefnagel BA, Delprat CC, Marcuse HR, de Vijlder JJM. Role of thallium-201 total-body scintigraphy in follow-up of thyroid carcinoma. J Nucl Med 1986;27:1854-1857.
2. Ramanna L, Waxman A, Braunstein G. Thallium-201 scintigraphy in differentiated thyroid cancer: Comparison with radioiodine scintigraphy and serum thyroglobulin determinations. J Nucl Med 1991;32:441-446.
3. Brendel AJ, Guyot M, Jeandot R, Lefort G, Manciet G: Thallium-201 imaging in the follow-up of differentiated thyroid carcinoma. J Nucl Med 1988;29:1515-1520.
4. Burman KD, Anderson JH, Wartofsky L, Mong D, Jelinek JJ: Management of patients with thyroid carcinoma: Application of TI-201 scintigraphy and magnetic resonance imaging. J Nucl Med 1990;31:1958-1964.
5. Charkes ND, Vitti RA, Brooks K. Thallium-201 Spect increases detectability of thyroid cancer metastases. J Nucl Med 1990;31:147-153.
6. Brendel AJ, Guyot M, Jeandot R, Lambert B, Lefort G, Roger P, Caudry M: Tc-99m MIBI imaging in the follow-up of differentiated thyroid carcinoma. 36th Annual Meeting. J Nucl Med 1989;30:904-905.
7. Van Sorge-Van Boxtel A J, Van Eck-Smit B L, Goslings M. Comparison of serum thyroglobulin, I-131 and TI-201 scintigraphy in the postoperative follow-up of differentiated thyroid cancer. Nucl Med Comm 1993;14:365-372.
8. Briele B, Hotze A, Kropp J, Overbeck B, Grünwald F, Kaiser W, Biersack H: Comparison of TI-201 and Tc-99m MIBI in the follow-up of differentiated thyroid carcinomas. Nucl-Med. 1991;30:115-124.
9. Sundram FX, Goh AS, Ang ES. Role of technetium-99m sestamibi in localisation of thyroid cancer metastases. Ann Acad Med Singapore 1993;22 (4):557-559.
10. Müller S, Guth-Tougelidis B, Creutzig H. Imaging of malignant tumors with Tc-99m-MIBI SPECT. J Nucl Med 1987;28:562(A).
11. Müller SP, Piotrowski B, Guth-Tougelides B, Reiners C. Tc-99m MIBI and TI-201 Uptake in thyroid carcinoma. J Nucl Med 1988;29:854(A).
12. Biedermann M, Bares R, Grün B, Dohmen BM, Sabri O, Friedberg C, Büll U. KST und Onkoszintigraphie mit Tc-99m MIBI in der Nachsorge des Schilddrüsenkarzinoms. Nucl Med 1995;34:87-91.
13. Meyer G, Lommatzsch B, Tiling R, Kleine U, Hahn K: Follow up of patients with differentiated thyroid carcinoma: The role of Tc-99m sestamibi scans in diagnosing metastases or local recurrence. Eur J Nucl Med 1995;22:769(A).
14. Platts EA, North TL, Pickert RD, Kelly JD: Mechanism of uptake of technetium tetrofosmin. Uptake into isolated adult rat ventricular myocytes and subcellar localizatization. J Nucl Cardiol 1995;2:317-326.
15. Yen T C, Lin H D, Lee CH, Chang SL, Yen SH: The role of Tc-99m sestamibi whole-body scans in diagnosing metastatic Huerthle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 an TI-201 whole body scans. Eur J Nucl 1994;21:980-998.
16. Dadparvar S, Krischna L, Brady LW, Chevres A, Khan AS: The role of I-131, thallium-201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma. Cancer 1993;71:3767-3773.
17. Highley B, Smith FW, Smith T, Gemmell HG, Gupta DG, Gvozdanovic DV, Graham D, Hinge D, Davidson J, Lahiri A: Technetium-99m-1,2-bis[bis (2- ethoxyethyl) phosphino] ethane: Human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993;34:30-38.
18. Civelek AC, Durski K, Shafique I, Matsumura K: Failure of perchlorate to inhibit Tc-99m isonitrile binding by the thyroid during myocardial perfusion studies. Clin Nucl Med 1991;16:358-361.
19. Wackers FHT, Berman DS, Maddahi J, Watson DD, Beller GA, Strauss HW, Boucher CA, Picard M, Holman BL, Fridrich R, Inglese E, Delaloye B, Bischof-Delaloye A, Camin L, McKusick K: Technetium-99m hexakis 2-mthoxyisobutyl isonitrile: Human biodistribution, dosimetry, safety, and preliminary comparison to Thallium-201 for myocardial perfusion imaging. J Nucl Med 1989;30:301-311.
20. Feine U, Lizenmayer R, Hanke JP, Wöhrle H, Müller-Schauenburg W: F-18 DG Ganzkörper-PET bei differenzierten Schilddrüsencarcinomen. Nucl Med 1995;34:127-134.
21. Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, Francese C, Fontaine F, Ricard M, Parmentier C: Radioactive iodine treatment and radiotherapy in 394 patients with lung and bone metastases. J Nucl Med 1996 in press
22. Hüfner M, Stumpf HP, Grussendorf M, Herman HJ, Kimming B: A comparison of the effectiveness of I-131 whole determination in a diagnosis for metastatic differentiated carcinoma of the thyroid: a retrospective study. Acta Endocrinol 1983;104:327-332.
23. Lubin E, Mechlis-Frish S, Zatz S, Shimoni A, Segal K, Avraham A, Levi R, Feinemesser R: Serum thyroglobulin and I-131 whole body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. J Nucl Med 1994;35:257-262.
24. Spies WG, Wojtowicz CH, Spies SM, Shah AJ, Zimmer M: Value of post-therapy whole body I-131 imaging in the evaluation of patients with thyroid carcinoma having undergone high dose iodine 131 therapy. Clin Nucl Med 1989;14:793-800.
25. Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C, Pinchera A: Therapeutic dose of I-131 reveal undiagnosed metastases in thyroid cancer patients with detecTable serum thyroglobulin level. J Nucl Med 1987;28:1888-1891.
26. Jeevanram RK, Shah DH, Sharma SM, Ganatra RD: Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Nucl Med Biol 1986;13:277-282
27. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J: Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995;80:1488-1492.
28. Linden A, Weiß R, Smolarz K, Jungehülsnig M, Theissen P, Schicha H: Bone marrow changes in patients with thyroid carcinoma. Nucl Med 1991;30:272-278.
29. Gallowitsch HJ, Kresnik E, Mikosch P, Lind P: Tc-99m Sestamibi and Tc-99m Tetrofosmin scintigraphy: alternative scintigraphic methods in follow up of DTC ? - First results. Eur J Nucl Med 1995;22:909(A).
30. Lind P, Gallowitsch HJ, Kresnik E, Mikosch P, Gomez I: Tc-99m tetrofosmin whole body scintigraphy in the follow up of differentiated thyroid carcinoma. J Nucl Med 1996, submitted.